Cygnet.One strengthens global e-Invoicing capabilities with expanded accreditations and enhanced support for Malaysia’s LHDN & MDEC framework 
Smmwiz Highlights Infrastructure Maturity as the SMM Panel Industry Evolves in 2026 
Enhancing the Front Door of Business Messaging 
HKTDC’s response to World Trade Organization’s latest report 
The Full Spectrum of K-Culture in One Place: “2026 MyK FESTA” to Open June 25 Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
The information contained within this announcement is deemed by the Company to constitute inside information…
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multi-epitopes. CoVepiT…
Polyphor to Present at the UBS Global Healthcare Virtual Conference
ALLSCHWIL, Switzerland, May 18, 2021 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) a research driven…
eureKARE launches with $60 million to build and finance next generation biotech companies in Europe
eureKARE launches with $60 million to build and finance next generation biotech companies in Europe…
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021
Monthly information regarding the total number of voting rights and total number of shares of…
Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results
PALATINE, Ill., May 17, 2021 (GLOBE NEWSWIRE) — Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative…
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session
REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence…
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
– Reported 50% response rate in visual sensitivity among patients in highest dose groups in…
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results
– ANX005 Huntington’s Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 –…
Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27
COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical…
Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced…
Codexis to Participate in Upcoming Virtual Healthcare Conferences
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq:CDXS), a leading enzyme…
ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq:…
Pacific Biosciences Further Expands Leadership Team with Appointment of Dr. Catherine Ball to Newly Created Position of Senior Vice President of Research
Kathleen Lynch has joined as Head of Global Government Affairs and Communications and Michele Farmer has…
Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update
– Recent New Drug Application Resubmission for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) – –…
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787
KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned…
Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to…
CohBar Reports First Quarter 2021 Financial Results and Provides Business Update
Company to host conference call at 5:00 p.m. ET MENLO PARK, Calif., May 17, 2021…
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of…